



DIGESTIVE CANCERS
EUROPE

Colorectal Cancer Screening: Lessons Learned from Covid-19

Dora Constantinides

Chair of the Board of Directors, DiCE


22 June 2021

 #EUHPP
@EU_Health

Digestive Cancers Europe (DiCE)

- Umbrella organisation of more than **30 national Member Organisations** from the WHO European Region
- Representing the digestive cancer patient community diagnosed with cancer of the **oesophagus, liver, stomach, pancreas, rectum, colon** and other **rare digestive cancers**
- Acting on behalf of **900.000 people who get a diagnosis of digestive cancer** every year in Europe, as well as the **1,5 million digestive cancer survivors**; also representing the families of the **600.000 patients who die** every year from digestive cancers

<https://www.digestivecancers.eu/>



Digestive Cancers in the EU




European Cancer Information System, 2020


Colorectal Cancer (CRC)



- The **2nd most common cancer** with the incidence predicted to rise significantly in the next decade
- The **2nd most common cause of cancer deaths**; highest mortality rates observed in Central and Eastern Europe
- CRC is both preventable and treatable



Total cost of CRC in the EU is 19 billion EUR



The costs of CRC
Factsheet

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.1. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer; 2014. <http://globocan.iarc.fr>,
 2. Hofmarcher, T., Lindgren, P. The Cost of Cancers of the Digestive System in Europe. IHE Report 2020:6. https://digestivecancers.eu/wp-content/uploads/2020/10/IHE_DiCE_HealthEcoStudy_2020.pdf
 3. GBD 2017 Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019; 4(12):913-933. doi: 10.1016/S2468-1253(19)30345-0

Call for Action on CRC Screening in the EU - The Joint Statement



Member States' Recommendations:


- The development of national implementation plans to achieve the committed goals of 65% participation rate among citizens 50–74 years old as a multidisciplinary and multi-stakeholder effort
- Invest in annual metrics for inputs and outcomes
- Invest in technologies and human resources
- Ensure that total health economic value is measured
- Ensure coherence and consistency of the political vision and health policy approaches at local and national levels

European Institutions' Recommendations

- Ensure that all EU Member States apply best practices in CRC screening
- Ensure that all EU Colorectal Cancer Screening Agencies join a common platform to exchange best practices

Other stakeholders

- Commit and participate to provide support, insights and expertise based on every stakeholder's competence and possibilities



The impact of Covid 19 on cancer screening

COVID-19 has had a massive impact on health, health provision and not least the provision of cancer screening.

Today we will hear how screening in a selection of countries has been affected, how the impact can relate to how screening is provided and how we might learn from this experience and build more effective screening programmes in the future!

Agenda

Time	Speaker	Title
10.00 – 10.05	Dora Constantinides Chair of the Board of Directors, DiCE	Welcome to the session
10.05 – 10.15	Prof. Dr. Eric Van Cutsem Head of Digestive Oncology, Leuven University Hospital, Belgium and Member of the Board of Digestive Cancers Europe	Introducing the session
10.15 – 10.30	European Commission: The Cancer Team	
10.30 – 10.40	Dr Tytti Sarkeala, Director of Screening, PhD Finnish Cancer Registry Finland	CRC screening and Covid-19 in Finland
10.40 – 10.50	Tit Albreht, MD, PhD, Senior Researcher, Joint Action Scientific Coordinator, National Institute of Public Health, Slovenia	The Impact of the Covid 19 pandemic on the Screening Programme in Slovenia
10.50 – 11.00	Dr. Iris Lansdorp-Vogelaar, Associate Professor at the Department of Public Health of Erasmus Medical Center, Rotterdam, Netherlands, and representing EU-TOPIA.	Screening under Covid-19 in the Netherlands
11.00 – 11.10	Dr. Carlo Senore Centro Prevenzione Oncologica Regione Piemonte and Azienda Ospedaliero-Universitaria S Giovanni Battista di Torino, Turin, Italy	CRC screening programmes in Europe under Covid-19
11.10 – 11.20	Prof. Dr. Stephen Halloran, Screening specialist, Member of the Bowel Cancer Screening Advisory Committee, United Kingdom	How can the lessons learned help us cope with future crises
11.20 – 11.50	ALL	Q&A session
11.50 – 12.00	Zorana Maravic, Acting CEO, Digestive Cancers Europe (DiCE)	The Way Forward

Housekeeping rules

Please note that this meeting will be recorded



Please **ALWAYS** keep your Microphone Muted when you are not speaking to reduce the background noise and disruption to the meeting! Use the WebEx controls to mute/unmute yourself:



You may have **your camera on or off** upon entrance into the meeting. It is at your discretion whether you would like to be visible to the group or not.

Please **use the “Chat” and or “Q&A”** feature to send any feedback directly to the Hosts or Moderators

Please note that the Power point Presentation will be shared by DiCE after the meeting

Thank you!

- Thank you to our speakers today for sharing the national and local experience of ‘cancer screening during COVID-19’.
- Thank you to the European Commission Cancer Team for your support and for recognising the critical contribution that effective screening programmes make to health at national level!
- Thank you to the audience! To all the participants sharing your time with us today for our common goal.